Since the early 1980s, phosphodiesterase 4 (PDE4) has been an attractive target for the
treatment of inflammation-based diseases. Several scientific advancements, by both …

Phosphodiesterase4 inhibitors are currently under development for the treatment of
respiratory diseases including asthma and chronic obstructive pulmonary disease. The …

Phosphodiesterase-4 (PDE4), mainly present in immune cells, epithelial cells, and brain
cells, manifests as an intracellular non-receptor enzyme that modulates inflammation and …

Introduction: At last, after many years of research, roflumilast has become the first oral
phosphodiesterase-4 inhibitor to be approved by the medical agencies as an add-on …

Publisher Summary This chapter focuses on phosphodiesterase-4 (PDE4) enzyme inhibitors
and their potential therapeutic utility. The chapter presents the in vitro pharmacology of …

Abstract Phosphodiesterase 4 (PDE4) belongs to a family of enzymes which catalyzes the
breakdown of 3, 5′-adenosine cyclic monophosphate (cAMP) and is ubiquitously …

The preregistration of roflumilast and the preapproval by the US Food and Drug
Administration of cilomilast highlight the continued, albeit slow, progress towards a selective …

Objectives: Identify FDA-approved indications for the administration of PDE5 inhibitors.
Describe the contraindications of PDE5 inhibitors. Summarize the mechanism of action of …

PDE4 inhibitors have been in development as a novel anti‐inflammatory therapy since the
1980s with asthma and chronic obstructive pulmonary disease (COPD) being primary …

Background: Despite the sound preclinical database and some promising data from clinical
trials, development of PDE4 inhibitors for the treatment of inflammatory or neurological …